Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=2&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder" }, "data": [ { "type": "Grant", "id": "10511", "attributes": { "award_id": "1U01CK000671-01", "title": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2025-09-29", "award_amount": 299761, "principal_investigator": { "id": 26517, "first_name": "Majid", "last_name": "Bani Yaghoub", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 753, "ror": "", "name": "UNIVERSITY OF MISSOURI KANSAS CITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Midwest Virtual Laboratory of Pathogen Transmission in Healthcare Settings (MVL-PATHS) Project Summary Antimicrobial Resistant (AMR) pathogens have become a significant public health threat. Also, the COVID-19 pandemic has further revealed disparities in healthcare settings. By developing and implementing novel mathematical and computation models, the long-term goals are to optimize AMR control and preventive interventions and to improve the health equity. The central hypothesis is that the outputs of mathematical and computation models will provide optimized and effective guidelines to reduce the threat of AMR pathogen spread and reduce health disparities in healthcare settings. The rationale underlying this project is to fill the critical gap in modeling workforce capacity and develop a new generation of mathematical models for healthcare research. The central hypothesis will be tested by pursuing three specific aims to develop and employ a, (i) One Health modeling approach to understand the source, distribution and spread of AMR Enterobacteriaceae with a focus on Extended- spectrum beta-lactamase (ESBL)-producing E. coli, (ii) a novel Real-Time modeling approach to identify AMR pathogen transmission by asymptomatic spreaders and contaminated medical devices in hospitals, (iii) a novel Agent-Based Nested modeling approach to identify the effects of caregivers as vectors of disease spread, and effects of limited staffing and specialized care on equitable quality of care in nursing homes. We will pursue these aims using an innovative combination of mathematical and computational modeling techniques. These include both recently developed techniques of including human behavior in models and more-established techniques that have been applied very little to the study of health equity and AMR pathogen spread. The workforce development objectives of this proposal are to (i) enhance mathematical and computational modeling research capabilities of the public health workforce and (ii) increase the number of junior modeling professionals that are trained and experienced in modeling transmission of pathogens in healthcare settings partly incorporated with health disparities. The expected outcomes of this work are the successful training of five predoctoral fellows and creating a virtual laboratory of enhanced mathematical models to identify strategies for reducing the threat AMR pathogen spread and reducing health disparities. The results will have an important positive impact immediately because the virtual laboratory can also be used by healthcare professionals to further investigate the drivers of disease spread and estimate the relative benefits of multiple control and prevention strategies in a timely and cost-effective manner. In addition, the research outputs of this project will expand and strengthen national one-health efforts to combat resistance and will have a direct impact on CDC and its public health partners’ ability to reduce the costs, morbidity and mortality of healthcare associated infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10639", "attributes": { "award_id": "3U54CA260581-02S1", "title": "Admin-Core-001", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 26691, "first_name": "Raymond D.", "last_name": "Harris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2025-08-31", "award_amount": 439872, "principal_investigator": { "id": 26692, "first_name": "JAMES E", "last_name": "Robinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 811, "ror": "", "name": "TULANE UNIVERSITY OF LOUISIANA", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "Overall Summary The SARS-CoV-2 virus, the causative agent of COVID-19, has infected a reported 13,810,247 persons globally as of July 16, 2020 with a mortality rate of 4.2%. In the State of Louisiana, over 7.3% of the 86,411 COVID-19 cases involve people living with cancer. Theoretically, convalescent plasma contains protective antibodies that neutralizes virus and mitigates its pathogenic effects. Yet, there remains a large gap in our understanding of the mechanisms that drive humoral and cellular immune responses and how these responses correlate with disease course and protection as well as the durability of those responses. Furthermore, there is a need for serological assays that measure these responses accurately for serodiagnosis and as correlates of immunity and protection. Without this knowledge, the true efficacy of convalescent plasma as therapy for COVID-19 and our understanding of the humoral immune response to SARS-CoV-2, especially in immunocompromised patients, will remain unknown. The overall goal of the Tulane University Convalescent Antibody and Immunity Network (TUCAIN) is to characterize this response with respect to functionality and durability. We will achieve this goal by investigating the following broad specific aims: (1) Characterize the evolution, function and longevity of the humoral immune response to COVID-19. (2) Identify cell mediated immune responses that contribute to durable or short-lived humoral immunity to SARS CoV-2. (3) Correlate protective and potentially pathogenic immune responses to the clinical course of hospitalized COVID-19 patients. We will achieve these goals by studying a diverse cohort of COVID-19 survivors and minimally sick seroconverters, including a large cohort of patients with malignancies. Using serial blood collections, we will apply several immunological technologies to study the evolution and durability of the immune response over time. We will also correlate these responses to patient outcomes and disease pathogenesis using a “big data”, systems biology approach. An approach, such as the one we propose, will allow us to determine if COVID-19 survivors develop long-term, antibody-based protection and we can confirm if convalescent plasma has therapeutic potential. This research will allow us to identify new targets for medicines and vaccines, inform personalized treatment strategies such as those required by immunocompromised patients with cancer, and to provide novel immunological algorithms applicable to a wide range of human pathogens.", "keywords": [ "2019-nCoV", "Address", "Advanced Development", "Algorithms", "Antibodies", "Antibody Response", "Antibody-mediated protection", "Applied Research", "Big Data", "Blood", "Blood specimen", "COVID-19", "COVID-19 patient", "COVID-19 survivors", "COVID-19 treatment", "Cellular Immunity", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Clinical Data", "Collection", "Data", "Data Set", "Development", "Diagnosis", "Disease", "Evolution", "Funding", "Goals", "Humoral Immunities", "Immune response", "Immunity", "Immunocompromised Host", "Immunologics", "Individual", "Infection", "Knowledge", "Longevity", "Louisiana", "Malignant Neoplasms", "Measures", "Medicine", "Memory", "Methods", "Mission", "Pathogenesis", "Pathogenicity", "Patient-Focused Outcomes", "Patients", "Persons", "Plasma", "Recurrence", "Reporting", "Research", "Risk", "SARS-CoV-2 immunity", "Serology test", "Serum", "Special Population", "Survivors", "Systems Biology", "Technology", "Therapeutic", "Time", "Universities", "Vaccines", "Viral", "Viral Hemorrhagic Fevers", "Virus", "base", "biobank", "cell mediated immune response", "cohort", "convalescent plasma", "coronavirus disease", "human pathogen", "improved", "insight", "longitudinal analysis", "mortality", "neutralizing antibody", "novel", "personalized medicine", "prevent", "programs", "public health emergency", "response", "screening", "therapeutic evaluation", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "10527", "attributes": { "award_id": "1R01MD016992-01A1", "title": "Addressing COVID 19 Vaccine Hesitancy in Rural Community Pharmacies Reducing Disparities Through an Implementation Science Approach", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-22", "end_date": "2025-05-31", "award_amount": 644347, "principal_investigator": { "id": 26537, "first_name": "GEOFFREY M", "last_name": "CURRAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26538, "first_name": "Delesha Miller", "last_name": "Carpenter", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "The COVID-19 pandemic has disproportionally impacted rural communities, which are often health professional shortage areas that lack health care infrastructure, including hospitals1-3. When compared to urban populations, individuals living in rural areas are more vaccine hesitant8,9, have a higher prevalence of comorbid health conditions that increase their risk for severe COVID-19 complications12, and are at greater risk from SARS-CoV-2 variants due to lower vaccination rates and fewer vaccination mandates33,40. Thus, interventions to increase vaccine uptake in rural areas are greatly needed. As the most accessible healthcare professional in rural areas4,5 and one of the most trusted sources of medication information16, community pharmacists are well-positioned to address vaccine hesitancy with underserved, rural populations. Because vaccination conversations are sensitive and often politically charged, pharmacists need implementation support, including training and ongoing guidance to deliver evidence-based vaccine hesitancy counseling interventions18. Implementation facilitation, in which trained facilitators coach and troubleshoot problems with professionals as they implement new practices, increases adoption of practices with fidelity23-26. However, implementation facilitation generally, and virtual facilitation (e.g., video coaching) in particular, has not been systematically studied in community pharmacy settings. The need to examine the effectiveness of virtual facilitation as a means to increase vaccine hesitancy counseling and COVID-19 vaccination is of great importance given the large travel distances to rural areas and social distancing. Our goal is to test if virtual facilitation increases rural pharmacists’ ability to implement COVID-19 vaccine hesitancy counseling when compared to a “standard” implementation approach (e.g., training and dissemination of implementation support tools). Using a rural pharmacy practice-based research network (PBRN) that spans 5 southeastern states, we propose two aims. Aim 1 involves a stepped-wedge trial with 30 rural pharmacies to test whether virtual facilitation outperforms the standard approach in increasing: (a) the fidelity with which pharmacists implement the vaccine hesitancy counseling intervention and (b) the number of vaccine hesitant patients who agree to receive the vaccine. Using a project-sponsored data collection system, we will gather data on implementation outcomes, including fidelity and effectiveness. In Aim 2, we will conduct a cost assessment to explore the sustainability of virtual facilitation. We are uniquely positioned to test these competing implementation approaches and leverage rural community pharmacists to engage in vaccine hesitancy counseling in rural communities that have low vaccination rates.", "keywords": [ "Address", "Adoption", "Ally", "Automobile Driving", "Budgets", "COVID-19 impact", "COVID-19 pandemic", "COVID-19 susceptibility", "COVID-19 vaccination", "COVID-19 vaccine", "Charge", "Communities", "Community Pharmacy", "Complex", "Cost Analysis", "Counseling", "Country", "Data", "Data Collection", "Dissemination and Implementation", "Effectiveness", "Effectiveness of Interventions", "Evidence based practice", "Feedback", "Goals", "Health", "Health Professional", "Healthcare", "High Prevalence", "Hour", "Human Papillomavirus", "Individual", "Infrastructure", "Intervention", "Modeling", "Monitor", "Patients", "Pharmaceutical Preparations", "Pharmacists", "Pharmacy facility", "Politics", "Positioning Attribute", "Primary Health Care", "Research", "Resources", "Risk", "Rural", "Rural Community", "Rural Population", "SARS-CoV-2 variant", "Safety", "Sampling", "Social Distance", "Source", "System", "Telephone", "Testing", "Time", "Training", "Travel", "Trust", "Update", "Urban Population", "Vaccination", "Vaccines", "Walking", "base", "comorbidity", "cost effective", "disparity reduction", "evidence base", "flu", "health care availability", "health professional shortage areas", "implementation facilitation", "implementation outcomes", "implementation science", "improved", "pandemic disease", "practice-based research network", "primary outcome", "rural area", "rural counties", "rural patients", "rural underserved", "secondary outcome", "severe COVID-19", "support tools", "vaccine acceptance", "vaccine hesitancy", "video coaching", "virtual" ], "approved": true } }, { "type": "Grant", "id": "10599", "attributes": { "award_id": "4R42MH127971-02", "title": "Developing an app-based behavioral intervention to help depressed individuals return to work", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 11535, "first_name": "Adam", "last_name": "Haim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2024-08-31", "award_amount": 664615, "principal_investigator": { "id": 24606, "first_name": "James William", "last_name": "Griffith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1760, "ror": "", "name": "INSPIRATION AT WORK, INC.", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24607, "first_name": "Alexandra", "last_name": "Levit", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24608, "first_name": "Stewart Aaron", "last_name": "Shankman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1760, "ror": "", "name": "INSPIRATION AT WORK, INC.", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Significance: The overarching goal of this proposal is to develop an intervention to help unemployed individuals with major depressive disorder (MDD) return to work. Individuals who lose their jobs are at risk for MDD and other psychiatric disorders. Because a core feature of MDD is decreased motivation, unemployed individuals with MDD can enter a `vicious cycle' where their depression leads to reduced motivation to seek work, which creates further financial hardship, which leads to worse depression and even suicide. The unprecedented impact that the COVID-19 pandemic has had on rates of depression and unemployment, has elucidated the clear need for interventions to help individuals with MDD return to work after getting laid off. Investigators: This STTR Fast Track grant brings together PeopleResults (a female-owned organizational development firm), diverse stakeholders (e.g., job seekers, community-based organizations), and Northwestern University researchers (e.g., psychologists, implementation and e-health scientists), to develop and test the efficacy of DRIVEN (Depression Return-to-work InterVEntioN). Innovation: DRIVEN is an innovative behavioral intervention that integrates evidenced-based strategies from cognitive-behavior therapy (e.g., behavioral activation techniques to improve positive affect and drive) with job-seeking and career counseling (e.g., interview coaching, how to customize job applications). DRIVEN will be a 6-week intervention largely delivered via a smartphone application (e.g., webinars, customized goals, with gamified features). However, given that e-health interventions are often plagued by high rates of attrition, DRIVEN will include multiple components designed to increase engagement, by increasing social support and accountability (e.g., biweekly live sessions with a job coach, email check-ins, gamified exercises, anonymous social media support platform). Our comprehensive commercialization plan also ensures that DRIVEN will reach job-seekers in need as it largely focuses on marketing to companies looking for outplacement services, i.e., resources provided by employers to recently laid off employees, in order to reduce the reputational fallout that companies risk following significant layoffs. Approach: Phase I will use user-centered design methodology (e.g., an advisory committee consisting of job-seekers, potential customers, experts in human resources) to design, develop, and alpha- and beta-test a prototype of DRIVEN. Phase II will test the efficacy of DRIVEN in a randomized controlled trial of 125 job seekers by comparing DRIVEN to a control condition consisting of self-guided job-seeking. Phase II will also utilize auto-regressive modelling with intensive longitudinal data to test for mediators of change (e.g., whether improvements in depression lead to greater job- seeking, and/or vice versa) Impact: DRIVEN will meet the high societal need resulting from the COVID-19 pandemic – helping the many unemployed Americans with MDD find meaningful and durable careers. While COVID-19 will (hopefully) be in the past by the end of this 3-year project, there will continue to be a need for interventions to help job-seekers with depression nimbly and successfully find work.", "keywords": [ "2019-nCoV", "Advisory Committees", "Affect", "American", "Anhedonia", "Behavior", "Behavior Therapy", "Behavioral", "Businesses", "COVID-19", "COVID-19 pandemic", "COVID-19 pandemic effects", "Cognitive", "Cognitive Therapy", "Communities", "Custom", "Data", "Depressed mood", "Development", "Dissemination and Implementation", "Electronic Mail", "Emotional disorder", "Employee", "Employment", "Ensure", "Evidence based treatment", "Exercise", "Exhibits", "Female", "Financial Hardship", "Goals", "Grant", "Health", "Hour", "Human Resources", "Individual", "Intervention", "Interview", "Job Application", "Lead", "Major Depressive Disorder", "Marketing", "Measures", "Mediator of activation protein", "Mental Depression", "Mental disorders", "Methodology", "Modeling", "Motivation", "Occupations", "Participant", "Persons", "Phase", "Private Sector", "Psychologist", "Randomized Controlled Trials", "Research Personnel", "Resources", "Risk", "Sampling", "Scientist", "Services", "Small Business Technology Transfer Research", "Social Accountability", "Social support", "Suicide", "Techniques", "Testing", "Treatment Efficacy", "Unemployment", "Universities", "Vocational Guidance", "Wages", "Work", "arm", "base", "career", "commercialization", "depressive symptoms", "design", "eHealth", "efficacy evaluation", "efficacy testing", "evidence base", "experience", "flexibility", "follow-up", "implementation efforts", "improved", "innovation", "multi-component intervention", "multidisciplinary", "novel coronavirus", "pandemic disease", "positive emotional state", "programs", "prototype", "psychologic", "response", "skills", "smartphone Application", "social media", "stressor", "suicidal risk", "therapy design", "therapy development", "treatment strategy", "user centered design", "webinar" ], "approved": true } }, { "type": "Grant", "id": "10543", "attributes": { "award_id": "1C06OD034121-01", "title": "National Ferret Research and Resource Institute (NFRRI) at University of Iowa", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 23882, "first_name": "CHARLES ASHLEY", "last_name": "Barnes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-05-31", "award_amount": 7975000, "principal_investigator": { "id": 26554, "first_name": "JOHN F", "last_name": "ENGELHARDT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 220, "ror": "https://ror.org/036jqmy94", "name": "University of Iowa", "address": "", "city": "", "state": "IA", "zip": "", "country": "United States", "approved": true }, "abstract": "While genetic mouse models have been the backbone of translational biomedical research for the past four decades, mice often fail to model human disease due to species-specific differences in the cell biology of the affected organs, as well as the evolutionary divergence of their genome. The ferret has proven an excellent species for modeling infectious disease (including SARS-CoV2) and human diseases of the brain, pancreas, and lung when mice have failed. The University of Iowa (UI) is the only location in the world capable of genetically engineering ferrets with multiple precise genetic alterations previously only achievable in mice. This technology has enabled the construction of genetic ferret models capable of fate mapping stem cell compartments (i.e., lineage tracing), modeling human diseases including those with humanized genetic loci, and conditional genetics using Cre recombinase. A federally-funded National Ferret Research and Resource Center was formed eight years ago, which provides services for the creation of new genetic ferret models, performing research studies in ferrets, and the distribution of tissues and cells from existing genetic lines. This national resource has provided services to more than 129 academic investigators,108 of which are outside the UI, and currently has 8 contracts with biotechnology companies seeking to develop therapies for genetic and acquired diseases using ferret models. These services have exceeded the capacity of facilities for both performing research in ferrets and housing ferrets on the UI campus. This proposal seeks to design and construct a research facility that will house the National Ferret Research and Resource Institute (NFRRI) on the UI campus. The proposed facility has been designed to maximize synergy and minimize overlap with existing facilities at UI and will be adjacent and connected to existing ferret expansion housing (referred to as the BSRF facility). The NFRRI will contain state- of-the-art equipment for genetically engineering ferret zygotes and performing research in ferrets. Procedural space will include a USDA-compliant sterile surgical suite and separate microinjection room for model creation. In addition to wet lab research space, specialized procedural suites will accommodate nebulization, pulmonary function testing, and specialized imaging equipment. The NFRRI will primarily provide services to academic investigators outside UI and for-profit biotechnology companies, but will also provide ferret models for research that will occur on the main UI campus in existing research facilities. Furthermore, the chosen location for the facility has adjacent land for future expansion of research space and ferret housing with a long-term strategic plan that recruits next-generation leaders of the NFRRI and capitalizes on existing relationships with for-profit biotechnology companies seeking to develop therapies for human diseases in preclinical ferret models. The short- and long-term strategic goals of the NFRRI will be facilitated through financial partnerships with the University of Iowa (cost sharing of the NFRRI building), Cystic Fibrosis Foundation, and Marshall Farms (the largest breeder of ferrets for research).", "keywords": [ "2019-nCoV", "Affect", "Biomedical Research", "Biotechnology", "Brain Diseases", "Cell Compartmentation", "Cells", "Cellular biology", "Contracts", "Cost Sharing", "Cystic Fibrosis", "Disease", "Drug or chemical Tissue Distribution", "Enterobacteria phage P1 Cre recombinase", "Equipment", "Farm", "Ferrets", "Foundations", "Funding", "Future", "Genetic", "Genetic Engineering", "Genome", "Goals", "Housing", "Image", "Institutes", "Iowa", "Location", "Lung diseases", "Microinjections", "Modeling", "Mus", "Mutation", "Nebulizer", "Operative Surgical Procedures", "Organ", "Pancreatic Diseases", "Pulmonary function tests", "Research", "Research Personnel", "Resources", "Services", "Sterility", "Strategic Planning", "Technology", "United States Department of Agriculture", "Universities", "Vertebral column", "design", "design and construction", "genomic locus", "human disease", "human model", "infectious disease model", "mouse model", "next generation", "pre-clinical", "recruit", "research facility", "research study", "stem cells", "synergism", "therapy development", "zygote" ], "approved": true } }, { "type": "Grant", "id": "10495", "attributes": { "award_id": "75N93022C00047-0-9999-1", "title": "REAL-TIME SURVEILLANCE OF VACCINE MISINFORMATION FROM SOCIAL MEDIA PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-08-08", "end_date": "2023-08-07", "award_amount": 300000, "principal_investigator": { "id": 26502, "first_name": "JINGCHENG", "last_name": "DU", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1763, "ror": "", "name": "MELAX TECHNOLOGIES, INC.", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "To develop digital tools to identify and combat malicious digital bots that spread misinformation about infectious disease treatments and vaccines, including COVID-19 vaccines.", "keywords": [ "Basic Science", "COVID-19 vaccine", "Coronavirus", "Misinformation", "Severe Acute Respiratory Syndrome", "Time", "Vaccines", "combat", "digital", "infectious disease treatment", "social media", "tool" ], "approved": true } }, { "type": "Grant", "id": "10591", "attributes": { "award_id": "1R01AI170839-01", "title": "Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 22533, "first_name": "Christopher E.", "last_name": "Beisel", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-09", "end_date": "2027-08-31", "award_amount": 531652, "principal_investigator": { "id": 26618, "first_name": "Jackie", "last_name": "Cliff", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26619, "first_name": "Eliana", "last_name": "Lacerda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1630, "ror": "", "name": "LONDON SCH/HYGIENE & TROPICAL MEDICINE", "address": "", "city": "", "state": "", "zip": "", "country": "UNITED KINGDOM", "approved": true }, "abstract": "/ ABSTRACT Our research project, entitled “Human Herpesvirus 6B in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome pathogenesis: temporal analysis of viral reactivation and immunity to elucidate cause vs effect”, aims to validate or refute the findings of our preliminary study on the role of human herpesviruses on the severity of symptoms in ME/CFS, and to determine if the virus reactivation is a cause or a consequence of the immune dysregulation. We will follow-up a larger number of consenting individuals (n=306), using our rigorous protocols designed to recruit participants to the UK ME/CFS Biobank (UKMEB). We have consent to re-contact UKMEB participants with ME/CFS (including those with a severe form of disease), and non-diseased controls (n=>500), with clinical assessments and collection of biosamples (blood and saliva). We will also recruit another comparison group, consisting of people with Long-COVID presenting with symptoms typical of ME/CFS (n=30), as well as people who did not develop long-term post-acute sequelae of COVID-19 after acute illness (Short COVID: n=30). The study population will comprise individuals from 18 - 60 years old, who have a diagnosis for ME/CFS or Long COVID with ME/CFS, as well as healthy controls and people who had Short COVID, in compliance with inclusion and exclusion criteria. We will perform a longitudinal analysis of people living with ME/CFS to determine the association and temporal relationship between HHV-6B DNA concentration and ME/CFS symptom severity, measuring viral DNA in saliva monthly for 6 months, alongside symptom scoring. To confirm that increases in HHV-6B DNA in saliva reflect systemic reactivation, we will measure blood viral RNA, DNA and protein, with the hypothesis that saliva RNA will correlate with saliva DNA concentration, and that all will increase together when ME/CFS symptoms are elevated. We will also measure frequency, phenotype and function of HHV-6B-reactive CD4+ and CD8+ T cells in people with ME/CFS. using flow cytometry, and will investigate the immunosuppressive effects of HHV-6B on antigen presentation in macrophages in ME/CFS using gene expression analysis. We hypothesize that HHV- 6B-specific T cells expand as ME/CFS symptoms worsen but are ineffective in for HHV-6B control, and we will test whether similar changes are observed in those with Long COVID in people who fulfill the diagnostic criteria for ME/CFS. Our goal, which stems from our successful pilot study, is to establish whether HHV-6B reactivation is causal in ME/CFS pathogenesis, and generate biological evidence which will inform targeted interventions such as vaccine development.", "keywords": [ "2019-nCoV", "Acute", "Adult", "Affect", "Antigen Presentation", "Antigen-Presenting Cells", "Bacterial Infections", "Biological", "Biological Assay", "Blood", "Blood specimen", "CD8-Positive T-Lymphocytes", "COVID-19", "Cell physiology", "Cells", "Characteristics", "Chemical Exposure", "Chronic Fatigue Syndrome", "Clinical", "Clinical assessments", "Collection", "Consent", "Cryopreservation", "DNA", "Data", "Data Collection", "Development", "Diagnosis", "Diagnostic tests", "Disease", "Endocrine", "Enrollment", "Etiology", "Event", "Evidence based treatment", "Exclusion Criteria", "Exertion", "Family member", "Fatigue", "Flow Cytometry", "Frequencies", "Funding", "Gene Expression Profiling", "Goals", "HHV-6B", "Herpesviridae", "Human", "Immune", "Immune response", "Immunity", "Immunologic Surveillance", "Immunologics", "Immunosuppression", "Individual", "Infection", "Interferon Type II", "Interleukin-2", "Intervention", "Knowledge", "Laboratories", "Life", "Long COVID", "Measures", "Multiple Sclerosis", "Mycoses", "Nature", "Outcome", "Participant", "Pathogenesis", "Patient Recruitments", "Peripheral Blood Mononuclear Cell", "Persons", "Phenotype", "Pilot Projects", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Prognostic Marker", "Proteins", "Protocols documentation", "RNA", "Recurrence", "Relapse", "Research Project Grants", "Role", "Saliva", "Salivary", "Severities", "Severity of illness", "Stress", "Symptoms", "Syndrome", "System", "T cell response", "T-Lymphocyte", "TNF gene", "Testing", "Time", "United States National Institutes of Health", "Viral", "Viral Markers", "Viral Proteins", "Virus", "Virus Diseases", "Work", "antigen-specific T cells", "base", "biobank", "clinical phenotype", "cohort", "comparison group", "coronavirus disease", "design", "diagnostic criteria", "digital", "epidemiology study", "follow-up", "inclusion criteria", "latent infection", "longitudinal analysis", "macrophage", "monocyte", "post SARS-CoV-2 infection", "recruit", "relating to nervous system", "saliva sample", "sample collection", "stem", "stressor", "study population", "vaccine development", "vaccine immunotherapy", "viral DNA", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "10551", "attributes": { "award_id": "1R21HD105886-01A1", "title": "Assessing Children’s Learning Achievement Using Remote Video Technology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 9683, "first_name": "REGINA M", "last_name": "BURES", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2024-08-31", "award_amount": 234000, "principal_investigator": { "id": 26563, "first_name": "PAULA W", "last_name": "FOMBY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "This study evaluates remote video interviewing as a mode to administer standardized tests of math and reading achievement to children age 5-17 years in their homes. The goal is to determine whether remote video interviewing should be offered as an alternative mode of standardized test administration in the next wave of the Child Development Supplement (CDS) to the Panel Study of Income Dynamics and will provide evidence about whether this approach offers an equivalent alternative to costly in-person administration with geographically dispersed or otherwise hard-to-reach samples. Standardized tests of math and reading performance offer valid and reliable measurement of a critical dimension of child development and reveal socially patterned disparities in learning achievement. To date in CDS, these tests have been administered in- person during field interviewers’ visits to children’s homes. But in-person administration has become increasingly challenging due to high travel and staffing costs associated with these visits in the geographically dispersed sample, respondents’ selective resistance to home visits, and constraints on in-person data collection arising from COVID-19. This project implements and evaluates remote video interviewing as a method to administer subtests from the Woodcock-Johnson IV Tests of Achievement (WJ-IV) to children. Sample members will be recruited through local advertising in geographic clusters selected throughout the country and in different types of rural, suburban, and urban areas in proximity to where experienced interviewers reside. Remote video interviewing will be achieved by mailing (with a prepaid return shipping box) an electronic tablet enabled with a cellular data connection to children in sample families. During a scheduled interview, children will use the tablet to interact with their interviewer via a videoconferencing interface, and the interviewer will present test stimuli via a screenshare from their own computer to the child’s tablet. The interviewer will record the child’s responses to stimuli in a programmed scoresheet. This mode of administration will be compared to conventional in-person administration with the same children using distinct but equivalent versions of the WJ-IV tests. The study team will evaluate within-person equivalence of test scores derived from the two modes of administration and the operational feasibility and efficiency of remote video administration with regard to cost, time, and task complexity.", "keywords": [ "Adopted", "Advertising", "Age", "COVID-19", "COVID-19 pandemic", "Charge", "Child", "Child Development", "Child Welfare", "Complex", "Computers", "Country", "Data", "Data Collection", "Dimensions", "Elderly", "Employment", "Evaluation", "Exhibits", "Family", "Fostering", "Geography", "Goals", "Health", "Home", "Home visitation", "Income", "Interview", "Interviewer", "Learning", "Life", "Location", "Mathematics", "Measurement", "Measures", "Methods", "Neighborhoods", "Parents", "Participant", "Pathway interactions", "Pattern", "Performance", "Personal Satisfaction", "Persons", "Population", "Poverty", "Privacy", "Quantitative Reasoning", "Reading", "Research", "Research Support", "Resistance", "Resources", "Respondent", "Risk", "Running", "Rural", "Sampling", "Schedule", "Schools", "Shipping", "Social Distance", "Social Policies", "Standardization", "Stimulus", "Stress", "Sum", "Surveys", "Tablets", "Technology", "Testing", "Time", "Training", "Travel", "Validity and Reliability", "Variant", "Videoconferencing", "Visit", "Work", "achievement test", "cognitive skill", "cohort", "cost", "cost efficient", "data infrastructure", "design", "ethnic minority", "experience", "falls", "improved", "innovation", "intervention program", "learning ability", "learning outcome", "mathematical ability", "member", "panel study of income dynamics", "peer", "preference", "prevent", "racial and ethnic", "racial minority", "reading ability", "recruit", "response", "social", "socioeconomics", "standardize measure", "suburb", "success", "urban area" ], "approved": true } }, { "type": "Grant", "id": "10631", "attributes": { "award_id": "1R01DA057567-01", "title": "Interpretable Deep Forecasting of Hazardous Substance Use during High School", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 10219, "first_name": "Vani", "last_name": "Pariyadath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2027-08-31", "award_amount": 498860, "principal_investigator": { "id": 26678, "first_name": "Kilian Maria", "last_name": "Pohl", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26679, "first_name": "SUSAN F", "last_name": "TAPERT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Substance use disorder (SUD) affects over 20 million Americans, causing personal strife and cost. A major SUD risk factor is hazardous use (HU) of substances during high school (HUSH), when the brain continues to develop, rendering it especially sensitive to environmental factors. Identifying the effects of and risk for HUSH generally focuses on selected interactions between fixed (i.e., trauma, demographics) and modifiable (i.e., mental health, emotion, environment, behavior, sleep) factors, and occasionally brain development features differentiating substance using and non-using cohorts. Results have yielded limited improvements to risk assessment. Thus, we propose a paradigm shift in the study of HUSH, replacing measurement selection and population splitting with mapping individuals to comprehensive multi-dimensional measures. The objective of our novel data-driven process is to identify constellations of fixed and modifiable factors forecasting HUSH in individuals. As our analysis is based on public data sets that include brain imaging, we will document interactions of those constellations with neural circuits to determine neuromechanistic underpinnings of HUSH. Myriad factors influence hazardous substance use, such as the fixed contributors of sex and family history of SUD; the modifiable factors of unhealthy sleep habits, peer pressure, and risk-taking propensity; and brain development characterized by an atypical imbalance between emotion and control network. We will model this heterogeneity via machine (deep) learning technology identifying constellations of measurements in line with our hypotheses regarding prevention, i.e., modifiable behaviors interacting with anomalies in neuroadaptation forecasting HUSH initiation. Aim 1 will forecast initiation of HUSH in the last years of high school based on the closest visit before turning age 16 years for no/low substance users in National Consortium on Alcohol and Neurodevelopment in Adolescence (NCANDA, N =350) and confirm findings on the larger Adolescent Brain Cognitive Developmental cohort (ABCD, N>11K). HUSH will be defined by substance use criteria recorded through annual self-reports and refined by weekly surveys administered via cell phones. Aim 2 will create a self-supervised learning model explicitly tracking over time interactions across modifiable behaviors, fixed factors, and brain circuits important for hypothesis testing. We will cross-validate the model by identifying HUSH for each high school year and forecast based on data collected prior to high school. We will explore dynamically updating the model as data are acquired to predict resilience, i.e., youth who abstain from hazardous substance use during high school, despite having risk factors such as traumatic and untoward COVID pandemic experiences. Each aim is linked to hypothesis testing concerning factors that can be altered to mitigate the risk of HUSH. This project will be the first to provide patterns accurately forecasting the risk of HUSH on an individual level. Accurately computing this risk would be foundational for enhancing prevention efforts.", "keywords": [ "16 year old", "Accounting", "Adolescence", "Adolescent", "Adverse effects", "Affect", "Age", "Alcohols", "American", "Attenuated", "Behavior", "Behavior Control", "Brain", "Brain imaging", "COVID-19 pandemic", "Cannabis", "Cellular Phone", "Cognition", "Cognitive", "Complex Analysis", "Data", "Data Set", "Development", "Developmental Delay Disorders", "Emotions", "Enrollment", "Environment", "Environmental Risk Factor", "Family history of", "Fibrinogen", "Foundations", "Future", "Hazardous Substances", "Health", "Heterogeneity", "High School Student", "Impulsivity", "Individual", "Link", "Machine Learning", "Magnetic Resonance Imaging", "Maps", "Measurement", "Measures", "Mediating", "Mental Health", "Modeling", "Motor", "Negative Reinforcements", "Participant", "Patient Self-Report", "Pattern", "Peer Pressure", "Population", "Positive Reinforcements", "Prevention", "Prevention program", "Preventive care", "Process", "Publishing", "Rewards", "Risk", "Risk Assessment", "Risk Factors", "Risk-Taking", "Site", "Sleep", "Structure", "Substance Use Disorder", "Surveys", "Symptoms", "Technology", "Testing", "Thinness", "Time", "Tobacco", "Trauma", "Update", "Visit", "Youth", "aged", "base", "boys", "brain volume", "cognitive control", "cognitive development", "cognitive testing", "cohort", "cost", "demographics", "experience", "follow-up", "frontal lobe", "girls", "high school", "learning strategy", "modifiable behavior", "morphometry", "neural circuit", "neuroadaptation", "neurodevelopment", "novel", "personalized approach", "poor sleep", "precision medicine", "resilience", "risk prediction", "sex", "sleep behavior", "substance use", "substance user", "supervised learning" ], "approved": true } }, { "type": "Grant", "id": "10559", "attributes": { "award_id": "1R01DA057052-01", "title": "Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21283, "first_name": "JULIA BETH", "last_name": "Zur", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-30", "end_date": "2026-06-30", "award_amount": 537775, "principal_investigator": { "id": 26575, "first_name": "Jan", "last_name": "Gryczynski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1945, "ror": "", "name": "FRIENDS RESEARCH INSTITUTE, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Methadone is an effective treatment for opioid use disorder (OUD) that is delivered in the U.S. through specialized Opioid Treatment Programs (OTPs). Since the inception of the OTP system many decades ago, federal regulations have required frequent clinic attendance to monitor patients’ response to treatment and reduce the risks of methadone diversion. Patients can only ‘earn’ take-home methadone after significant time in treatment while demonstrating rigid standards for adherence and stability. However, these classic regulations are not grounded in strong empirical evidence. The COVID-19 pandemic transformed service delivery practices at OTPs. To reduce crowding in clinics, SAMHSA regulators swiftly issued regulatory exemptions that gave OTPs unprecedented discretion to provide take-home methadone doses and deliver counseling via telehealth. OTPs were suddenly permitted to dispense up to 14 days of take-home methadone for ‘less stable’ patients, and 28 days for ‘stable’ patients. More recently, SAMHSA reaffirmed the regulatory exemptions and announced intentions to pursue permanent regulatory reform for OTPs. However, research is needed to examine the scope and impact of these major changes to care delivery. This study will (1) characterize practice changes at OTPs following the COVID-19 pandemic and the issuance of regulatory exemptions, (2) Examine the relationship of two major practice changes (expanded take-home methadone and telehealth practices) and patient outcomes, (3) develop a prediction model to inform decision- making about when patients can safely receive take-homes without increasing risk of negative outcomes, and (4) examine the relationship between expanded take-home methadone and methadone overdose deaths at a population level. The study will use clinical and administrative data from BayMark Health Services, the largest provider of outpatient OUD treatment in the U.S., with 100 OTPs in 23 states. Advanced analytical methods will be applied to answer the research questions, including multilevel generalized linear mixed modeling, predictive modeling and simulation methods, and interrupted time series. All analyses will consider behavioral health equity and examine disparities with respect to patients’ sex, race, and ethnicity. This study will provide critical data for regulators, OTP administrators, and practitioners. It will yield highly novel data to support evidence-driven regulatory reform, and could shape methadone treatment delivery over the next decade and beyond. The COVID-19 pandemic and associated federal exemptions offer an unprecedented opportunity to evaluate long-held assumptions about how methadone treatment should be structured to maximize its benefits while safeguarding patients and the public from unintended harm.", "keywords": [ "Adherence", "Administrator", "Admission activity", "Affect", "Area", "Behavioral", "COVID-19", "COVID-19 pandemic", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Clinic", "Clinical", "Coronavirus", "Counseling", "Crowding", "Data", "Death Records", "Decision Making", "Dose", "Dropout", "Drug usage", "Ethnic Origin", "Frequencies", "Goals", "Health Benefit", "Health Services", "Health Services Accessibility", "Healthcare Systems", "Home", "Individual", "Interruption", "Link", "Medicine", "Methadone", "Methods", "Modeling", "Monitor", "Opioid", "Outcome", "Outpatients", "Overdose", "Pain", "Patient Care", "Patient Monitoring", "Patient-Focused Outcomes", "Patients", "Persons", "Pharmaceutical Preparations", "Policies", "Population", "Positioning Attribute", "Provider", "Public Health", "Race", "Regulation", "Relapse", "Research", "Risk", "Series", "Shapes", "Structure", "System", "Time", "Travel", "United States Substance Abuse and Mental Health Services Administration", "advanced analytics", "analytical method", "behavioral health", "care delivery", "care seeking", "combat", "coronavirus disease", "drug testing", "effective therapy", "health equity", "indexing", "methadone treatment", "models and simulation", "mortality", "novel", "opiate tolerance", "opioid mortality", "opioid overdose", "opioid treatment program", "opioid use disorder", "overdose death", "overdose risk", "post-COVID-19", "predictive modeling", "premature", "public health emergency", "response", "service delivery", "sex", "telehealth", "transmission process", "treatment response", "trend", "willingness" ], "approved": true } } ], "meta": { "pagination": { "page": 2, "pages": 1442, "count": 14420 } } }